Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 3, 2012, Pages 187-194

  Kaemmerer, Daniel ^a   Peter, Luisa ^a   Lupp, Amelie ^b   Schulz, Stefan ^b   Sänger, Jörg ^c   Baum, Richard Paul ^d   Prasad, Vikas ^e   Hommann, Merten ^a  

^a Zentralklinik Bad Berka ^*  (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Laboratory of Pathology and Cytology   (Germany)

^d ZENTRALKLINIK BAD BERKA   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gastroenteropancreatic neuroendocrine tumors; Her2 score; Immunohistochemistry; IRS; Somatostatin receptors; UMB 1 antibody

Indexed keywords

68GA DOTANOC; 68GA-DOTANOC; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; KI 67 ANTIGEN; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DIGESTIVE SYSTEM TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING;

DIGESTIVE SYSTEM NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861215384     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A and Delle Fave G. Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 2009; 89: 223-230.
2. Reubi JC. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004; 80 Suppl 1: 51-56.
3. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S and Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005; 52: 605-611.
4. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL and Bussolati G. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reversetranscriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461-475.
5. Reubi JC, Laissue J, Waser B, Horisberger U and Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994; 733: 122-137.
6. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
7. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y and Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002; 50: 52-60.
8. Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Mendez G and Roca E; Buenos Aires and La Plata Argentina Argentum Working Group. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010; 42: 220-225.
9. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M and Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 48-52.
10. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Prasad V, Kulkarni H, Haugvik SP, Hommann M and Baum RP. Molecular imagingwith Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011; 38: 1659-1668.
11. Baum RP, Prasad V, Hommann M and Horsch D. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 2008; 170: 225-242.
12. Prasad V, Fetscher S and Baum RP. Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view. J Pharm Pharm Sci 2007; 10: 321s-337s.
13. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R and Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
14. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
15. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A and Papotti M. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007; 20: 1172-1182.
16. Pisarek H, Pawlikowski M, Kunert-Radek J and Winczyk K. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynol Pol 2010; 61: 178-181.
17. Thodou E, Kontogeorgos G, Theodossiou D and Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 2006; 59: 274-279.
18. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-140.
19. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R and Schulz S. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 2008; 93: 4519-4524.
20. Schulz S, Schreff M, Schmidt H, Handel M, Przewlocki R and Hollt V. Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. Eur J Neurosci 1998; 10: 3700-3708.
21. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C and Hollt V. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998; 4: 2047-2052.
22. McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
23. Reubi JC, Schaer JC, Waser B and Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994; 54: 3455-3459.
24. Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E and Lamberts S. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 1992; 74: 1082-1089.
25. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793.